Oxxon Therapeutics, Inc. announced today that data would be presented at the 56th Annual Meeting of The American Association for the Study of Liver Diseases (AASLD) on Monday November 14th in a plenary session. Oxxon will present positive interim data from a Phase IIa, 52-week study of its novel therapeutic vaccine comprising a PrimeBoost immunotherapeutic approach in patients with chronic hepatitis B. The study, which was conducted in two parts, found the therapy was safe and generally well tolerated. Overall, these data show that at 14 weeks, Oxxon’s PrimeBoost immunotherapy alone elicited hepatitis B antigen loss in 9/40 (23%) of patients as compared to only 1/11 (9%) of those who received lamivudine alone. In addition, no patient receiving lamivudine had seroconverted by week 14 whereas 5/40 (13%) of patients having received immunotherapeutic alone had done so. This seroconversion rate was sustained to at least week 26 - longer-term follow up continues.
